Skip to content

Exploring the osteoporosis treatment gap after fragility hip fracture at a Tertiary University Medical Center in Thailand

A study evaluating the persistence rate of osteoporosis treatment with anti-osteoporosis drug in patient who had osteoporotic hip fracture

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20210824002
Enrollment
322
Registered
2021-08-24
Start date
2021-03-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistence rate of anti-osteoporosis drug treatment in hip fracture patient Osteoporosis, Hip fracture

Interventions

Patient who initiate the treatment after received the prescription and persistent to medication.,Patient who did not initiate the treatment after received the prescription.,The patient whom had alrea
Other,Other,Other
Persistence,Primary Non-persistence,Secondary Non-persistence

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Previous osteoporotic hip fracture patient whom admitted and operated in Siriraj hospital 2. Age 50 years old or more 3. At least 1 year follow-up period

Exclusion criteria

Exclusion criteria: 1. Pathological hip fracture 2. Atypical femoral fracture 3. High energy injury 4. Inability to communicate

Design outcomes

Primary

MeasureTime frame
Persistence rate 1 year Prescription of anti-osteoporosis agent

Secondary

MeasureTime frame
Reason of non-persistence 1 year Reason of discontinuation of anti-osteoporosis agent

Countries

Thailand

Contacts

Public ContactEkasame Vanitcharoenkul

Faculty of Medicine Siriraj Hospital

artvanit@gmail.com024197968

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026